Injection site reactions Redness, swelling, or itching at the injection site affects a small percentage of users
Retatrutide In Phase 2 trials, Retatrutide produced: Up to 24.2% weight loss after 48 weeks at higher doses Strong dose dependent responses across study groups A proportion of participants lost 15% or more of their body weight, particularly at the upper dose ranges
Pilot clinical studies and case reports describe nausea in 65% of subjects at doses above 0,5 mg (resolution 2-4 h post-injection), flushing in 55%, transient increases in blood pressure and tachycardia in 40-60% of subjects, with peak acute effects occurring 90-120 minutes post-dose
Most patients require between two and five sessions of Aqualyx to achieve their desired outcome, benefiting from a track record of safety and long-lasting efficacy that remains unmatched by social media trends
Peptide Therapy Peptide treatments offer targeted metabolic support for fat loss, energy, muscle tone, and appetite regulation
If you use oral hormonal contraceptives, discuss this with your prescriber, as data from the tirzepatide SmPC suggest that additional contraceptive precautions may be advisable during initiation and dose escalation of GLP-1/GIP-based therapies, pending specific retatrutide data